

Substitute for FORM 1449A/B/PTO		Complete if Known			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number:	10/084,638		
(Use as many sheets as necessary)		Filing Date:	February 27, 2002		
Sheet 1 of 2		First Named Inventor:	Michael Babich		
		Group Art Unit:	1644		
		Confirmation Number:	3698		
		Examiner Name:	Rooney, Nora Maureen		
		Attorney Docket Number:	21511-92177		

U.S. PATENT DOCUMENTS					
Examiner Initials	Doc. No.	U.S. Patent Document	Application or Patent Number	Kind Code	Name of Patentee or Applicant
					Date of Publication
					Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Translation
							Yes	No <sup>++</sup>

OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.				Translation
B 1		AAAI Work Group Report, "Current Approach to the Diagnosis and Management of Adverse Reactions to Foods," <i>American Academy of Allergy Asthma &amp; Immunology, Obtained from Internet: http://www.aaaai.org/media/resources/academy_statements/practice_papers/allergy_diagnosis.pdf</i> (2003).				Yes No <sup>++</sup>
B 2		Babich et al., "In vitro Translation and Computational Analyses of Human Profilin Multimers," <i>Proc. West. Pharmacol. Soc.</i> , 48: 39-43 (2005).				
B 3		Bhalla et al., "Engineered allergens for immunotherapy," <i>Current Opinion in Allergy and Clinical Immunology</i> , 4: 569-573 (2004).				
B 4		Gould et al., "The Biology of IgE and the Basis of Allergic Disease," <i>Annu. Rev. Immunol.</i> , 21: 579-628 (2003).				
B 5		Holm et al., "Allergy Vaccine Engineering: Epitope Modulation of Recombinant Bet v 1 Reduces IgE Binding but Retains Protein Folding Pattern for Induction of Protective Blocking-Antibody Responses," <i>The Journal of Immunology</i> , 173: 5258-5267 (2004).				
B 6		Kay, A.B., "An Extract of Timothy-Grass Pollen Used as Sublingual Immunotherapy for Summer Hay Fever," <i>Drugs of Today</i> , 43 (12): 841-848 (2007).				
B 7		Kazemi-Shirazi et al., "Recombinant Marker Allergens: Diagnostic Gatekeepers for the Treatment of Allergy," <i>Int. Arch. Allergy Immunol.</i> , 127: 259-268 (2002).				
B 8		Kirkland et al., "Evaluation of the Proline-Rich Antigen of <i>Coccidioides immitis</i> as a Vaccine Candidate in Mice," <i>Infection and Immunity</i> , 66 (8): 3519-3522 (1998).				
B 9		Mahler et al., "Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1," <i>Clin. Exp. Allergy</i> , 34: 115-122 (2004).				
B 10		Malling et al., "Immunotherapy as an effective tool in allergy treatment," <i>Allergy</i> , 53: 461-472 (1998).				
B 11		Petersen et al., "Post-translational modifications influence IgE reactivity to the major allergen Ph1 p 1 of timothy grass pollen," <i>Clinical and Experimental Allergy</i> , 28: 315-321 (1998).				
B 12		Pomes et al., "Can knowledge of the molecular structure of allergens improve immunotherapy?," <i>Current Opinion in Allergy and Clinical Immunology</i> , 1: 549-554 (2001).				
B 13		Sankian et al., "Sequence homology: A poor predictive value for profilins cross-reactivity," <i>Clinical and Molecular Allergy</i> , 3 (13): Obtained from Internet: http://www.biomedcentral.com/1476-7961-3-13 (2005).				

EXAMINER	DATE CONSIDERED
----------	-----------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →

Substitute for FORM 1449A/B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number:	10/084,638
(Use as many sheets as necessary)		Filing Date:	February 27, 2002
Sheet 2 of 2		First Named Inventor:	Michael Babich
		Group Art Unit:	1644
		Confirmation Number:	3698
		Examiner Name:	Rooney, Nora Maureen
		Attorney Docket Number:	21511-92177

B 1 4	Scheurer et al., "Cross-reactivity within the profiling panallergen family investigated by comparison of recombinant profilins from pear (Pyr c 4), cherry (Pru av 4) and celery (Api g 4) with birch pollen profilin Bet v 2," <i>Journal of Chromatography B</i> , 756: 315-325 (2001).		
B 1 5	Shinnick et al., "Synthetic Peptide Immunogens as Vaccines," <i>Ann. Rev. Microbiol.</i> , 37: 425-446 (1983).		
B 1 6	Sly et al., "Changing prevalence of allergic rhinitis and asthma," <i>Annals of Allergy, Asthma, &amp; Immunology</i> , 82: 233-252 (1999).		
B 1 7	Valenta et al., "The Immunoglobulin E-Allergen Interaction: A Target for Therapy of Type I Allergic Disease," <i>Int. Arch. Allergy. Immunol.</i> , 116: 167-176 (1998).		
B 1 8	Valenta et al., "Identification of Profilin as a Novel Pollen Allergen; IgE Autoreactivity in Sensitized Individuals," <i>Science</i> , 253: 557-560 (1991).		
B 1 9	van Ree, Ronald, "Clinical importance of cross-reactivity in food allergy," <i>Current Opinion in Allergy and Clinical Immunology</i> , 4: 235-240 (2004).		
B 2 0	Vrtala et al., "Strategies for converting allergens into hypoallergenic vaccine candidates," <i>Methods</i> , 32: 313-320 (2004).		
B 2 1	WHO Position Paper, "Allergen immunotherapy: therapeutic vaccines for allergic diseases," <i>American Academy of Allergy Asthma &amp; Immunology, Obtained from Internet: <a href="http://www.eaaci.net/media/PDF/W275.pdf">http://www.eaaci.net/media/PDF/W275.pdf</a></i> (1997).		

CHDS01 AOM 466451v1

EXAMINER	DATE CONSIDERED
----------	-----------------

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).